The Effect of Pimecrolimus Cream 1% Compared with Triamcinolone Acetonide Paste in Treatment of Atrophic-Erosive Oral Lichen Planus

Document Type: Original

Authors

1 Oral and Maxillofacial Diseases Research Center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Oral Medicine Specialist, DDS MSc, San Diego, USA.

3 Department of Oral Medicine, Faculty of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Dentist, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction:
Oral lichen planus (OLP) is a common chronic mucocutaneous disease. Patients with atrophic and erosive types of OLP often have symptoms of soreness, and require proper treatment. The main treatment for OLP has been the administration of topical or systemic corticosteroids. The objective of this study was to compare the efficacy of adcortyl cream (triamcinolone acetonide in orabase) with topical pimecrolimus cream for the treatment of erosive OLP.
 
Materials and Methods:
Twenty-eight patients with OLP were enrolled in a single blind clinical trial and assigned to either a pimecrolimus 1% cream group or an adcortyl 0.1% cream group. The medication was applied every day for 2 months and patients were assessed every 2 weeks.
 
Results:
The mean lesion size and mean pain and burning sensation scores did not differ between the pimecrolimus and adcortyl cream groups. The pimecrolimus cream was well tolerated. No clinical drug-related adverse events were observed.
 
Conclusion: 
Topical pimecrolimus cream may be recommended as a safe and effective alternative therapy in the treatment of OLP. Pimecrolimus cream is as effective as adcortyl cream in managing the signs and symptoms of OLP.

Keywords


1. Axéll TZain RBSiwamogstham PTantiniran DThampipit J. Prevalence of oral soft tissue lesions in out-patients at two Malaysian and Thai dental schools. Community Dent Oral Epidemiol 1990; 18(2):95-9.

2.  Bánóczy JRigó O. Prevalence study of oral precancerous lesions within a complex screening system in Hungary. Community Dent Oral Epidemiol 1991; 19(5):265-7.

3.   Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002; 46(2): 207-14.

4.  Greenburg MS, Glick M, Ship JA. Burket's oral medicine.11th ed. Hamilton: BC Decker Inc; 2008. p. 89-95.

5.  Volz TCaroli ULüdtke HBräutigam MKohler-Späth HRöcken Met al. Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. Br J Dermatol  2008; 159(4):936-41.

6. Silverman S JrGorsky MLozada-Nur F. A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol 1985; 60(1):30-4.

7. Shen ZYLiu WZhu LKFeng JQTang GYZhou ZT. A retrospective clinicopathological study on oral lichen planus and malignant transformation: analysis of 518 cases. Med Oral Patol Oral Cir Bucal 2012;17(6):e943-7.

8. Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus  and clobetasol in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105(2):187-93.

9. McCaughey CMachan MBennett RZone JJHull CM. Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. J Eur Acad Dermatol Venereol 2011; 25(9):1061-7.

10.  Lodi GCarrozzo MFurness SThongprasom K. Interventions for treating oral lichen planus: a systematic review. Br J Dermatol2012; 166(5):        938-47.

11.   Azizi ALawaf S. The comparison of efficacy of adcortyl ointment and topical tacrolimus in treatment of erosive oral lichen planus. J Dent Res Dent Clin Dent Prospects 2007;1(3):99-102.

12.  Ruzicka TAssmann THomey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999;135(5):574-80.

13.  Laeijendecker RTank BDekker SKNeumann HA. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 2006;86(3):227-9.

 14. Shichinohe RShibaki ANishie WTateishi YShimizu H. Successful treatment of severe recalcitrant erosive oral lichen planus with topical tacrolimus. J Eur Acad Dermatol Venereol 2006; 20(1): 66-8.

 15. Thongprasom KLuangjarmekorn LSererat TTaweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992;21(10):456-8.

 16.  Scully CEisen DCarrozzo M.Management of oral lichen planus. Am J Clin Dermatol 2000; 1(5):287-306.

 17.  Becker JCHouben RVetter CSBröcker EB. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 2006; 6:7.

18.   Mattsson UMagnusson BJontell M. Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod  2010; 110(1):e19-25.

19.  Passeron T, Lacour JP, Fontas E, Ortonne JP. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol 2007;143(4):   472-6.

20. Swift JCRees TDPlemons JMHallmon WWWright JC. The effectiveness of 1%  pimecrolimus cream in the  treatment  of  oral  erosive lichen planus. J Periodontol 2005;76(4):627-35.

21.   Gorouhi F, Solhpour A, Beitollahi JM, Afshar S, Davari P, Hashemi P, et al.  Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol 2007;57(5):806-13.